MX2020007050A - Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas. - Google Patents

Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas.

Info

Publication number
MX2020007050A
MX2020007050A MX2020007050A MX2020007050A MX2020007050A MX 2020007050 A MX2020007050 A MX 2020007050A MX 2020007050 A MX2020007050 A MX 2020007050A MX 2020007050 A MX2020007050 A MX 2020007050A MX 2020007050 A MX2020007050 A MX 2020007050A
Authority
MX
Mexico
Prior art keywords
immunoglobulin
combination
prevention
antigen
treatment
Prior art date
Application number
MX2020007050A
Other languages
English (en)
Inventor
Geoffrey William Hoffmann
Reginald M Gorczynski
Original Assignee
Network Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Network Immunology Inc filed Critical Network Immunology Inc
Publication of MX2020007050A publication Critical patent/MX2020007050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al uso de inmunoglobulina plasmática, tal como inmunoglobulina intramuscular, en combinación con inmunoglobulina policlonal específica de antígeno en el tratamiento o prevención de enfermedad alérgica. La invención también se refiere a una composición farmacéutica constituida por inmunoglobulina plasmática en combinación con inmunoglobulina policlonal específica de antígeno.
MX2020007050A 2018-01-05 2019-01-04 Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas. MX2020007050A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862614131P 2018-01-05 2018-01-05
PCT/CA2019/050013 WO2019134047A1 (en) 2018-01-05 2019-01-04 A combination of plasma immunoglobulin and antigen- specific immunoglobulin for the modification of the immune system and the treatment or prevention of allergic diseases

Publications (1)

Publication Number Publication Date
MX2020007050A true MX2020007050A (es) 2020-11-11

Family

ID=67143486

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007050A MX2020007050A (es) 2018-01-05 2019-01-04 Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas.

Country Status (9)

Country Link
US (1) US20200353081A1 (es)
EP (1) EP3735273A4 (es)
JP (2) JP2021509918A (es)
CN (1) CN111565753A (es)
BR (1) BR112020013381A2 (es)
CA (1) CA3086860A1 (es)
IL (1) IL275714A (es)
MX (1) MX2020007050A (es)
WO (1) WO2019134047A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9885360B2 (en) 2012-10-25 2018-02-06 Pentair Flow Technologies, Llc Battery backup sump pump systems and methods
US20220356232A1 (en) * 2019-06-28 2022-11-10 Network Immunology Inc. A combination of plasma immunoglobulin and antigen-specific immunoglobulin for the modification of the immune system and the treatment or prevention of autoimmune diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE897227A (fr) * 1982-07-13 1984-01-06 Sandoz Sa Traitement des troubles allergiques
KR20070108320A (ko) * 2006-03-20 2007-11-09 전숙영 알레르기질환 및 자가면역질환의 치료를 위한 약학적조성물, 그의 용도 및 알레르기질환 및 자가면역질환의치료방법
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
GB2490652A (en) * 2011-04-18 2012-11-14 Microtest Matrices Ltd Methods of quantifying antibodies, especially IgE antibodies in a sample
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN105770890A (zh) * 2016-03-08 2016-07-20 苏文全 一种特异性蛋白质组合物及其使用方法

Also Published As

Publication number Publication date
EP3735273A1 (en) 2020-11-11
JP2023139175A (ja) 2023-10-03
IL275714A (en) 2020-08-31
WO2019134047A1 (en) 2019-07-11
CN111565753A (zh) 2020-08-21
US20200353081A1 (en) 2020-11-12
BR112020013381A2 (pt) 2020-12-01
JP2021509918A (ja) 2021-04-08
CA3086860A1 (en) 2019-07-11
EP3735273A4 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
MX2023014569A (es) Anticuerpos anti-sirpa.
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
MY196224A (en) Human Antibodies To Ebola Virus Glycoprotein
EP4223774A3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
MX2017003211A (es) Anticuerpos anti-met y composiciones.
MX2019004779A (es) Composicion farmaceutica para tratamiento y/o prevencion de cancer.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
PH12018500098A1 (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
WO2020106358A8 (en) Novel anti-zika virus antibodies and uses thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
MX2020007050A (es) Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas.
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2017013879A (es) Composiciones que comprenden anakinra.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2022000317A (es) Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5.
EA202092149A1 (ru) Композиции, содержащие бактериальные штаммы
NZ629683A (en) Methods for treating conditions associated with masp-2 dependent complement activation